News | April 06, 2022
AGC to invest $100 million for expanding synthetic pharmaceutical production in Spain
The new facility is scheduled to start operation in the first half of 2024
The new facility is scheduled to start operation in the first half of 2024
The organization has introduced an advanced FlashMicelle technology which is a combination of ultra-rapid mixing techniques, and a uniquely powerful approach to modify the structure of oil-based formulations to improve their therapeutic efficacy substantially
Arzeda harnesses the power of computer-designed enzymes and applies the latest advances in digital biology
The plant is scheduled to come on stream in September 2024
The new structure further transitions the Health Care business line into a system solutions partner for the pharmaceutical and biotech industries
Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
Saransh Chaudhary, President, Global Critical Care Division, Venus Remedies and CEO, Venus Medicine Research Centre In conversation with Thomas C Thottathil, Editor, www.indianpharmapost.com identified key areas that the company is focusing on in its Mission 2025
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Subscribe To Our Newsletter & Stay Updated
